NeuVasQ was founded based on new insights into the molecular mechanisms maintaining the integrity of the blood-brain barrier (BBB). The BBB regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in many neurological conditions through the leakage of harmful blood substances into the CNS. BBB dysfunction is a factor in many neurodegenerative disorders, such as Alzheimer’s, as well asmultiple acute neurological conditions like stroke and epilepsy.
The company will develop first-in-class pharmaceuticals exploring different therapeutic modalities based on gene, RNA, small molecules or antibody/protein construct. Proof-of-Concept data of Animal models for stroke and glioblastoma have been published in the academic journal “Science”.



EditForce developed a unique DNA/RNA editing technology, based on a pentatricopeptide repeat (PPR) protein platform technology, which has a distinct feature that enables the editing of not only DNA but also RNA, highlighting its difference compared to other technologies. It has different mechanisms to work and isolated intellectual property from other existing DNA/RNA editing technologies. RNA editing technology could be an intervention to treat diseases derived from RNA splicing abnormality and abnormal repeat-RNA sequence, or diseases known to result from mutations susceptible to cure by single base editing technology, which PPR could achieve. The platform technology is expected to be applied to a wide range of fields.